皮尔托布鲁丁尼:B细胞恶性瘤的新型和独特的治疗选择
Madeline D Schultze1, David J Reeves1,2
1College of Pharmacy & Health Sciences, Butler University, Indianapolis, IN, USA.
The Annals of pharmacotherapy
|January 18, 2024
概括
皮尔托布鲁替尼在治疗B细胞恶性瘤 (如地幔细胞淋巴瘤和慢性淋巴细胞白血病) 中表现出有效性,即使在耐其他布鲁顿氨酸激酶 (BTK) 抑制剂的患者中也是如此. 这种非共价BTK抑制剂为复发或耐火病例提供了新的选择.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- B细胞恶性瘤是癌症研究的一个重要领域.
- 布鲁顿的氨酸激酶 (BTK) 抑制剂已经成为一种关键的治疗类.
- 对现有的BTK抑制剂的耐药性需要开发新药.
研究的目的:
- 评估皮尔托布鲁丁尼布在B细胞恶性瘤的疗效和安全性.
- 为了区分皮尔托布鲁替尼与其他可用的布鲁顿氨酸激酶 (BTK) 抑制剂.
- 评估皮尔托布鲁替尼在患有对先前BTK抑制剂耐药性的患者中的有效性.
主要方法:
- 在PubMed和ClinicalTrials.gov.gov上进行了全面的文献搜索.
- 搜索词包括皮尔托布鲁替尼,杰皮尔卡和LOXO-305.
- 选择并分析了相关的英语临床试验.
主要成果:
- 皮尔托布鲁丁尼在慢性淋巴细胞白血病 (CLL) 中的整体响应率 (ORR) 为73%,在地幔细胞淋巴瘤 (MCL) 中为58%.
- 该药物在先前接受过共价BTK抑制剂治疗或对共价BTK抑制剂耐药的患者中显示出有效性.
- 常见的不良反应包括疲劳,腹,出血和感染;心房动可能较少发生.
结论:
- 皮尔托布鲁丁尼 (Pirtobrutinib) 有效治疗复发性/耐药性B细胞恶性瘤,包括MCL和CLL.
- 它的非共价结合和选择性比早期的BTK抑制剂具有优势.
- 目前正在进行的试验可能会扩大其在各种B细胞恶性瘤中的应用.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K


